- Home
- KPTI vs FCO Comparison
KPTI vs FCO Comparison
Compare KPTI & FCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- FCO
- Stock Information
- Founded
- KPTI 2008
- FCO 1991
- Country
- KPTI United States
- FCO United Kingdom
- Employees
- KPTI N/A
- FCO N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- FCO Investment Managers
- Sector
- KPTI Health Care
- FCO Finance
- Exchange
- KPTI Nasdaq
- FCO Nasdaq
- Market Cap
- KPTI 102.4M
- FCO 85.6M
- IPO Year
- KPTI 2013
- FCO N/A
- Fundamental
- Price
- KPTI $6.29
- FCO $2.99
- Analyst Decision
- KPTI Strong Buy
- FCO
- Analyst Count
- KPTI 7
- FCO 0
- Target Price
- KPTI $31.71
- FCO N/A
- AVG Volume (30 Days)
- KPTI 302.2K
- FCO 100.1K
- Earning Date
- KPTI 11-11-2025
- FCO 01-01-0001
- Dividend Yield
- KPTI N/A
- FCO 14.96%
- EPS Growth
- KPTI N/A
- FCO N/A
- EPS
- KPTI N/A
- FCO 0.43
- Revenue
- KPTI $137,269,000.00
- FCO N/A
- Revenue This Year
- KPTI $3.40
- FCO N/A
- Revenue Next Year
- KPTI $9.69
- FCO N/A
- P/E Ratio
- KPTI N/A
- FCO $12.30
- Revenue Growth
- KPTI N/A
- FCO N/A
- 52 Week Low
- KPTI $3.51
- FCO $4.73
- 52 Week High
- KPTI $16.95
- FCO $6.63
- Technical
- Relative Strength Index (RSI)
- KPTI 53.09
- FCO 29.22
- Support Level
- KPTI $5.71
- FCO $2.81
- Resistance Level
- KPTI $6.75
- FCO $3.09
- Average True Range (ATR)
- KPTI 0.58
- FCO 0.07
- MACD
- KPTI 0.03
- FCO 0.13
- Stochastic Oscillator
- KPTI 81.25
- FCO 64.31
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About FCO abrdn Global Income Fund Inc.
abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories, Developed Markets, Investment Grade Developing Markets and Sub-Investment Grade Developing Markets.